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A B S T R A C T
The oxidative modification of apolipoprotein A-I’s methionine148 (M148) is associated with defective
HDL function in vitro. Multiple reaction monitoring (MRM) is a mass spectrometric technique that can be
used to quantitate post-translational modifications. In this study, we developed an MRM assay to monitor
the abundance ratio of the peptide containing oxidized M148 to the native peptide in ApoA-I.
Measurement of the oxidized-to-unoxidized-M148 ratio was reproducible (CV < 5%). The extent of
methionine M148 oxidation in the HDL of healthy controls, and type 2 diabetic participants with and
without prior cardiovascular events (CVD) were then examined. The results suggest a significant increase
in the relative ratio of the peptide containing oxidized M148 to the unmodified peptide in the HDL of
participants with diabetes and CVD (p < 0.001), compared to participants without CVD. Monitoring the
abundance ratio of the peptides containing oxidized and unoxidized M148 by MRM provides a means of
examining the relationship between M148 oxidation and vascular complications in CVD.
ã 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Contents lists available at ScienceDirect
Translational Proteomics
journa l homepage: ht tp : / /www.e l sev ier .com/ loca te / t rprot1. Introduction
Cardiovascular disease (CVD) is the leading cause of mortality in
the U.S, and diabetes is an important risk factor [1]. Recent trials
examining the impact of intensive glycemic control on the
reduction of CVD endpoints [2–4] highlight the challenges for
reducing the increased CVD risk, and the need for new biomarkers
of diabetic complications. Several studies suggest that the function
of HDL is defective in diabetes [5]. Shao et al. demonstrated that
the ability of apolipoprotein A-I (ApoA-I) to activate LCAT is
impaired by methionine oxidation of residue 148, M148(O) [6].
LCAT esterifies cholesterol on HDL and is an important componentAbbreviations: HDL, high density lipoprotein; CVD, cardiovascular disease;
ApoA-I, apolipoprotein A1; MRM, multiple reaction monitoring.
$ This is an open-access article distributed under the terms of the Creative
Commons Attribution-NonCommercial-No Derivative Works License, which
permits non-commercial use, distribution, and reproduction in any medium,
provided the original author and source are credited.
* Corresponding author. Tel.: +1 323 444 1909; fax: +1 323 444 2808.
E-mail address: hyassine@usc.edu (H.N. Yassine).
http://dx.doi.org/10.1016/j.trprot.2014.10.001
2212-9634/ã 2014 The Authors. Published by Elsevier B.V. This is an open access article unfor reverse cholesterol transport [7]. Thus, ApoA-I methionine
oxidations are potential markers of diabetic complications.
Mass spectrometry (MS)-based applications are particularly
well-suited to measure post-translational modifications of
proteins [8]. Conventional MS-based quantitation workflows
using spectral counting or extracted ion chromatograms involve
lengthy MS data acquisition and analysis times and are often
limited to quantifying differences between small sample sets.
Hence, there is a need to develop high-throughput assays with
simple sample preparation and reduced MS analysis time.
Multiple reaction monitoring (MRM) is a tandem MS (MS/MS)
scan mode unique to triple quadrupole MS instrumentation that
is capable of rapid, sensitive, and specific quantitation of peptides
in highly complex sample matrices, such as plasma [9,10]. MRM is
a targeted approach that requires knowledge of the molecular
weight the peptide of interest and its fragmentation pattern,
leading to the generation of target “transitions” for monitoring
protein levels.
In this study, we defined the transitions for monitoring the ratio
of oxidized M148 to its unmodified peptide in ApoA-I using MRM.
We applied this technology to HDL samples from the plasma ofder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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events to determine if this ratio was higher in diabetic participants
with vascular complications.
2. Methods
The study was approved by the University of Arizona
Institutional Review Board, and all participants provided written
informed consent prior to testing.
2.1. Clinical samples
The plasma samples were collected at University of Arizona
diabetes Clinics and from the community. Thirty-four participants
(8 healthy controls, 11 with type 2 diabetes and 15 with both
diabetes and a prior CVD event) reported to the Center for Clinical
and Translational Sciences (CaTS) after an overnight fast. CVD
events were defined by a prior history of coronary artery bypass
surgery (CABG), percutaneous transluminal angioplasty (PTCA),
prior MI, or thrombotic stroke as previously defined in major
clinical trials [11]. The study excluded subjects if they met any of
the following criteria: had type 1 diabetes, were on an active
weight loss program, history of cancer, HIV, or steroid use. All study
participants had oral glucose tolerance tests (OGTTs). New
diagnosis of diabetes was based on fasting blood sugar >125 mg/
dL, 2 h OGTT >200 mg/dL or HbA1c >6.5%. Established diabetes was
defined by clinical history. All non-diabetic participants partici-
pating underwent oral glucose testing. The subjects were asked to
fill a physical activity questionnaire [12] regarding if they
participated in a structured exercise program, the type of exercise
and its frequency per day or week. None of the patients recruited
were participating in a structured exercise program. In their
questionnaires, the majority of subjects did not report daily
exercise activities. Participants did not engage in high intensity
exercise for at least 2 days prior to testing. Plasma samples were
collected in EDTA tubes between 2008 and 2009, and were
immediately frozen at 80 C. Sample analysis by mass spectrom-
etry was done in 2011 at University of Arizona and University of
Victoria proteomics cores.
2.2. HDL isolation technique
HDL isolation by centrifugation was based on a modification
of a previously published protocol [13]. In brief, KBr (~55 mg)
was added to 310 mL of plasma samples to create a density of
1.21 g/mL. The sample was overlaid with 200 mL of 1.21 g/mL
density solution for a total volume of 500 mL. Samples were then
spun at 120,000 rpm, at 16 C for 2 h (Beckman TLX ultracentri-
fuge with a type 120.1 fixed angle rotor using thick-walled
500 mL polycarbonate tubes, item 343776). The upper 125 mL
solution that had a density of less than 1.21 g/mL was removed
and 150 mL of NaCl/EDTA solution (0.9% (w/v) NaCl, 0.1% (w/v)
EDTA, pH 7.4) was added to each tube for a final density of
1.063 g/mL. Subsequently, 225 mL of 1.06 KBr solution in NaCl/
EDTA was added creating a final volume of 500 mL for a second
2 h spin at the same parameters listed. The bottom 125 mL (HDL
fraction) of solution was removed for further analysis. We
confirmed that albumin and apolipoprotein B (Apo B) were
depleted in the HDL isolate using MRM and four HDL samples
were sent to Myriad RBM to externally validate our measure-
ments using an immunoassay in a CLIA certified laboratory. HDL
proteins were measured using the method of Lowry. HDL
samples were submitted in a 96 well plate in 100 mL aliquots
with a final protein concentration of 0.3 mg/mL.2.3. MRM analysis
2.3.1. Developing ApoA-I M148 peptide transitions for MRM
This method was developed at the University of Arizona’s
proteomics core facility. An HDL isolate from a control
participant was screened for methionine oxidations (M148:
oxidation + 16 defined as M148(O)) and the transitions from
theoretical fragmentation patterns using Prospector were obtained.
Three transitions for M148(O) peptide had signal-to-noise (S/N)
ratio >3. The modified peptides of M148(O) were then synthesized
(New England Peptides, Gardner, MA). By infusing the peptides into
the mass spectrometer, the transitions of the modified peptides
were then optimized and the peaks were confirmed in MRM mode
as previously described [8]. Following confirmation of in vivo
peaks, stable-isotope-labeled standard (SIS) peptides for M148(O)
were synthesized. In addition to monitoring the methionine
containing ApoA-I peptides, a second ApoA-I peptide (ATEHLSTL-
SEK), a peptide for Apo B100 (FPEVDLIK) and albumin peptide
(LVNEVTEFAK) were monitored to assess the quality of the HDL
isolate. These experiments were completed at University of Arizona
proteomics core. An extensive list of plasma protein transitions for
MRM use has been previously published [10].
2.3.2. MRM analyses
One control sample and thirty-five HDL samples were sent to
University of Victoria – Genome BC Proteomics Centre which has a
dedicated MRM service. Eight replicate MRM runs of a control
sample were done to determine the coefficient of variation (CV) of
the target peptides measurements. All HDL samples were run once
and analyzed in one batch in 2011.
2.4. Sample preparation prior to LC/MRM-MS
Samples were first diluted by the addition of 140 mL of 37.5 mM
ammonium bicarbonate to each 100 mL of sample. Each diluted
HDL sample was denatured by adding 30 mL of 10% w/v sodium
deoxycholate (NaDOC) in 37.5 mM ammonium bicarbonate.
Disulfide bonds were reduced by the addition of 7.46 mL of
50 mM tris (2-carboxyethyl) phosphine (TCEP, in 37.5 mM ammo-
nium bicarbonate), and incubation at 60 C for 30 min in a dry-air
incubator. Free sulfhydryl groups were alkylated by the addition of
8.28 mL of 100 mM iodoacetamide (in 37.5 mM ammonium
bicarbonate), and incubation at 37 C for 30 min in a dry-air
incubator. Any remaining iodoacetamide was quenched by the
addition of 8.28 mL of 100 mM DTT (in 37.5 mM ammonium
bicarbonate)and incubation at 37 C for 30 min in a dry-air
incubator. Six micro liter of sequencing-grade trypsin (0.4 mg/mL
(Promega) in 37.5 mM ammonium bicarbonate) was added to each
sample. The final volume of each digest was 300 mL, and digestion
was conducted at 37 C for 16 h in a dry air incubator.
2.5. SIS peptide addition & solid phase extraction
Digestion was stopped by the addition of an acidified SIS peptide
mixture in formic acid, to give a final formic acid concentration of
0.5% v/v and to reduce the pH to <3, which inactivates trypsin and
precipitates NaDOC). Two nanogram of methionine oxidized SIS
peptides were spiked into the sample per MRM run. Samples were
centrifuged for 10 min at 12,000  g (23 C) to remove the NaDOC
precipitate. The supernatant containing the peptides was desalted
and concentrated by solid phase extraction using Waters Oasis HLB
1 cc columns (10 mg). The eluted samples were frozen and
lyophilized to dryness overnight. Prior to the LC/MRM-MS analysis,
samples were rehydrated in a volume of Solvent A (0.1% v/v formic
acid) to obtain a concentration of 0.5 mg/mL of original sample.
Table 1
Peptides monitored by MRM.
Target Q1 Q3 DP CE Peptide Ion CV(%)
Albumin 575.3 937.5 70 25 LVNEVTEFAK y8 5.2
Apo B-100 524.3 450.8 55 28 FPEVDVLTK y82+ 20
ApoA-I 405.9 522.3 52 18 ATEHLSTLSEK y9 3.2
ApoA-I 405.9 572.8 52 19 ATEHLSTLSEK y102+ 1.2
M148 516.3 416.2 60 30 LSPLGEEMR y72+ 1.5
M + 148(O) = M148 + 16 524.3 424.4 60 27 LSPLGEEM(O)R y72+ 3.8
M + 148(O) = M148 + 16 524.3 637.3 60 33 LSPLGEEM(O)R y5 4.2
M + 148(O) = M148 + 16 524.3 750.4 60 33 LSPLGEEM(O)R y6 4.7
The CVs were calculated from 8 replicate analyses of a control sample. DP: declustering potential; CE: collision energy; CV: coefficient of variation.
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The MS analyses were performed on an AB/MDS Sciex 4000
QTRAP equipped with an Eksigent NanoLC-1Dplus LC system.The
trapping column used was a 5  0.3 mm C18 PepMap column, with
5 mm particles (Dionex/LC Packings). The analytical column was a
75 mm  150 mm Reprospher 100 C18 Aqua column, packed with
3 mm particles, 100 Å pore size, packed in-house under argon. The
solvent system consisted of solvent A (100% H2O, 0.1% v/v formic
acid), and solvent B (90% aqueous acetonitrile, 0.1% v/v formic acid).
The on-line analyses were 43 min in length and the gradient was
constructed as follows: samples were loaded onto the trapping
column at 10 mL/min (2% aqueous acetonitrile, 0.1% v/v aqueous
formic acid) for 3 min, followed by a 2 min linear gradient from 3% toFig. 1. Representative chromatogram of M148 (LSPLGEEMR) peptides in a control HDL
Unmodified M148 (y72+) together with in vivo oxidized peptides (y72+,y5 and y6) and the
shows two peaks. The larger of these two peaks co-elutes with the other modified and13% solvent at 300 nnL/min, a 10 min linear gradient at 300 nL/min
from 13% to 20% solvent B, a 9 min linear gradient at 300 nL/min from
20% to 27% solvent B, and a final 6 min linear gradient at 300 nL/min
from 27% to 44% solvent B before high organic column flushing and
re-equilibration. A blank solvent injection was run between all
samples to prevent sample carryover on the HPLC column. An AB/
MDS Sciex 4000 QTRAP with a Michrom Captive Spray source,
controlled by Analyst 1.5 software (Applied Biosystems) was used for
all of the LC/MRM-MS analyses. All acquisition methods used the
following instrument parameters: 1300–1500 V ion spray voltage, a
110 C interface heater temperature, an MS operating pressure of
3.5 105 Torr, and Q1 and Q3 set to unit resolution (0.6–0.8 Da
FWHH). MRM acquisition methods were constructed using 1 or 2 ion
pairs per peptide with empirically-tuned DP and CE voltages for each sample showing the intensity of the peaks (y axes) and retention time (x axes).
 corresponding heavy peptides (y72+, y5 and y6) are shown. Note the M148(O) y72+
 heavy peptide peaks and this was selected for quantification.
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all MRM ion pairs, with a target cycle time of 2 s.
2.7. MRM data acquisition
All MRM data was processed using MultiQuant 1.2 (Applied
Biosystems) with the MQL algorithm for peak integration.
Automatic peak detection, 3-point Savitsky–Golay smoothing, a
peak-splitting factor of 2, and default MultiQuant values for the
noise percentage and baseline subtraction window were used. All
integrated peaks were manually inspected to ensure correct peak
detection and integration.
2.8. Statistical analysis
The statistical program R was used. The M148 oxidation
ratios, and the triglyceride were not normally distributed and the
analysis was completed on log transformed data. The transitions
for the modified and unmodified ApoA-I peptides were
correlated using pearson coefficients. M148 y72+ transition was
used for data analysis. Biochemical and MRM measures were
compared using ANOVA with p-value <0.05. Linear models were
used to calculate the p values of the correlated variables.
The M148 oxidation ratio and HDL ApoA-I were the primary
endpoint and the statistical significance was assessed at theTable 2
Study characteristics and measurements. The p value in the table refers to all three g
superscripts, and are explained in the footnote below.
Characteristic Non-diabetic controls (n = 8)
Group 1
Participants w
(n = 11) Group 
Demographic profile
Sex 3 males, 5 females 4 males, 7 fem
Race 6 Caucasians, 2 Hispanics 8 Caucasians, 2
Age (years) 48  13 56  13 
Body mass index (kg/m2) 25  3 34  6 
–
Vital signs
Systolic blood pressure (mm Hg) 110  14 123  12 
Diastolic blood pressure (mm Hg) 76  8 77  7 
–
Medications (# of participants)
Statins 0 0 
Metformin 0 2 
Insulin 0 2 
Aspirin 0 1 
Beta blockers 0 2 
ACE inhibitors or ARBs 0 4 
–
Biochemical profile
Fasting glucose (mg/dL) 95  12 142  57b
OGTT (mg/dL)d Fasting = 93  10
2 h post = 135  31
Hemoglobin A1c (%) 5.1  0.27 7.6  2.9b
Fasting insulin (IU) 7  3 12  7 
HDL cholesterol (mg/dL) 70  14 53  16bc
LDL cholesterol (mg/dL) 117  31 125  21 
Triglycerides (mg/dL) 116  87 146  64 
C-reactive protein (mg/L) 4  4 7  5 
HDL apolipoprotein A-I (mg/dL) 127.5  25 90  40 
M148 oxidation relative ratio e 0.087  0.02 0.127  0.037b
M148 oxidation and HDL ApoA-I were the primary endpoint and the statistical significanc
considered significant to adjust for multiple comparisons.
ACE: angiotensin converting enzyme; ARB: angiotensin receptor blocker.
Values are means  SD.
ANOVA group comparisons were followed by Tukey group-wise comparisons when th
a p < 0.05 type 2 diabetics with CVD vs. non-diabetics;
b p < 0.05 type 2 diabetics without CVD vs. non-diabetics.
c p < 0.05 type 2 diabetics with CVD vs. Type 2 diabetics without CVD
d OGTTs were only performed in non-diabetic subjects
e The results were not corrected for possible ex vivo oxidation of methionine0.05 level. For the other measurements or recorded data, a p value
of 0.005 or less was considered significant to adjust for multiple
comparisons.
3. Results
Using theoretical transitions derived from MS Prospector, an
HDL sample was screened for M148 and M148(O) peptides and a
signal-to-noise (S/N) ratio >3 was observed. To validate these
peaks, modified and SIS peptides for M148(O) were synthesized
and the transitions were optimized. The MRM transitions are
summarized in Table 1. An HDL sample was then monitored for
M148 oxidations. As shown in Fig. 1, the in vivo oxidized peaks
had near identical retention times to the heavy peptides (SIS)
providing peak validation with three transitions for M148(O)
peptide. Of the three M148(O) transitions, the y72+ ion showed the
highest peak intensity, but had two peaks. Only one of these peaks
eluted at the same retention time of the other M148(O) transitions
and that of the added SIS peptides. This co-eluting peak was
selected for quantitation. This finding highlights the need for
multiple transitions per peptide in addition to added SIS peptides
for correctly identifying the peak of interest when using MRMs.
Although we used an S/N ratio of >3 to screen for the oxidized
M148 peptide, the in vivo M148(O) peak observed after MRM
transitions optimization was several fold (10-fold) greater thanroups being compared with each other. Pairwise comparisons are shown by the
ith diabetes
2
Participants with diabetes and CVD
(n = 15) Group 3
p
(for comparison)
ales 8 males, 7 femalesa 0.03
 Hispanics, 1 Asian 10 Caucasians, 5 Hispanics 0.24
53  12 0.38
39  12a 0.005
132  13a 0.002
79  11 0.71
7ac <0.001
5 0.1
2 0.2
7a 0.001
6a 0.002
7a 0.003
202  88a <0.001
8.4  2.9a 0.009
16  13a 0.04
39  8a <0.001
111  43 0.67
212  138 0.11
13  12 0.23
84  39a 0.029
0.236  0.084a <0.001
e was assessed at the 0.05 level. For the other measures, a p value of 0.005 or less was
e p for the three-comparison was <0.05:
Fig. 2. The distribution of oxidized M148 relative ratio among the three disease groups. The mean M148(O) ratio to native peptide in diabetes and CVD group was significantly
greater than both the control and diabetes group without CVD (*p < 0.001 for both comparisons).
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three M148 transitions were highly correlated with each other
(r  0.95, p < 0.001). To determine the reproducibility of the MRM
assay, 8 replicates of a control sample were analyzed. The MRM
assay for M148(O) ratio was highly reproducible (Table 1, M148(O)
CV <5%), and the transition with the best CV (y72+) was used to
compare the relative ratio of the oxidized methionines among the
study groups.
A second ApoA-I peptide (ATEHLSTLSEK) was used to measure
ApoA-I concentrations on HDL. The correlation between the peak
area of ATEHLSTLSEK to unmodified M148 peptides was weak
(r = 0.42, p < 0.001), possibly due to the susceptibility of methio-
nine residues to oxidation. To validate the measurement of protein
concentrations using MRM, four HDL samples were sent to Myriad
RBM that has a CLIA certified laboratory with the ability of running
multiplexed immunoassays. Concentrations of albumin, Apo B100,
and ApoA-I (ATEHLSTLSEK) measured using the multiplexed
immunoassays at Myriad were strongly correlated to measure-
ments by MRM (r > 0.95, p < 0.001 for all three proteins). The ratio
of ATEHLSTLSEK peptide to the corresponding SIS peptide was
used to calculate the concentrations of ApoA-I on HDL (Table 2) in
the clinical samples. SIS peptides for the unmodified M148 was not
synthesized, and thus we were unable to determine ApoA-I
concentrations based on the M148 peptide.
Thirty-four participants were recruited to examine the impact
of disease on ApoA-I methionine oxidations. As shown in Table 2,
controls were leaner, and had a lower systolic blood pressure
(p < 0.005). Participants with diabetes and heart disease were
taking more statins, aspirin, and blood pressure medication
compared to controls or diabetics without a prior history of a
cardiac event. Participants with diabetes and CVD had significantly
decreased HDL ApoA-I concentrations compared to participants
with diabetes but without CVD (p = 0.029 for the group comparison
by ANOVA, and p = 0.027 for the group with CVD vs. diabetes
without CVD). The relative ratio of oxidized to native M148 peptide
in HDL was three times as high in the diabetes and CVD group, and
1.5 times as high in the diabetic group without prior CVD,compared to the control group (p < 0.001 for the group comparison
by ANOVA, with p < 0.001 for both diabetes and CVD vs. control,
and for diabetes without CVD vs. control, Fig. 2).
4. Discussion
In this study, we defined MRM transitions to monitor the
relative ratio of M148 oxidations compared to M148 peptide on
ApoA-I. Our results demonstrated that monitoring the relative
ratio of the M148(O)- to the M148-containing peptide was highly
reproducible with a CV <5% using MRM. We did not measured the
molar % oxidized M148 in this proof-of-concept study, because
this would have required absolute quantitation of both forms of
this peptide. Clinically, HDL isolated from participants with
diabetes and CVD had a significantly increased ratio of oxidized
M148 to unoxidized M148. These proof-of-concept findings
suggest a role for M148(O) as a biomarker for CVD; however,
larger clinical studies are needed to validate this role. M148 lies at
the center of LCAT activation domain. Shao et el. demonstrated
that oxidation of M148(O) was associated with decreased
capacity to activate LCAT [6]. In addition, reversing
M148 oxidation using methionine sulfoxide reductase restored
the ability of ApoA-I to activate LCAT. We monitored the changes
in ApoA-I M148 oxidations in HDL isolates rather than whole
serum since HDL is the site where LCAT activity esterifies
cholesterol, and changes of oxidation status in this local
environment may have a functional relevance.
Measuring oxidized M148 using conventional mass spectrom-
etry methods that utilize spectral counting or extracted ion
chromatograms can be lengthy and challenging in large sample
sizes. In contrast, MRM is a promising technique that allows
multiplexing of several targets and has been successfully applied
to quantitate plasma proteins [10,14]. The addition of SIS peptides
in MRM allows for absolute quantitation. Since our goal was to
develop an assay to assess the relative ratio of oxidized M148
to the native peptide rather than the absolute concentrations,
the SIS peptide for the unmodified M148 was not synthesized.
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the in vivo M148 peaks, and optimize the transitions. The
rationale for not determining the absolute concentration of M148
(O) in plasma was that this concentration can vary because of
variations in the ApoA-I concentration. In contrast, monitoring
the relative ratio of oxidized M148 to the non-oxidized peptide
represents the “quality” of this peptide, is cost-effective and
simple with less inherent variability. Thus, this approach is better
suited for comparing M148 oxidation ratios among different
patient groups. One advantage of MRM is that different peptide
variants can be selected, depending on the goal of the particular
project. The M148-containing ApoA-I peptide would not normally
be selected for ApoA-I quantitation because of its susceptibility to
methionine oxidation. The “ATEHLSTLSEK” ApoA-I peptide likely
gives a better estimate of total ApoA-I concentration.
Several limitations of the study deserve mention. First, we
have not measured the molar % oxidized of M148, as such
measure would require calibration of both forms of the peptide.
Second, methionines are susceptible to ex vivo oxidation that can
result from inadequate or prolonged freezing, repeated thawing,
or centrifugations [15]. Because an anti-oxidant solution was not
immediately added before freezing the samples or after HDL
isolations, this might have permitted additional oxidation. The
ratios of methionine oxidation observed in our study were higher
than those reported in an earlier study on diabetes where the
samples were preserved in an anti-oxidant solution prior freezing
[16]. In this earlier study, however, younger patients with type
1 diabetes were recruited. We have recently demonstrated that
immediate freezing of samples at 80 C without the use of an
anti-oxidant solution results in low levels of ApoA-I oxidation
that are stable for up to 2 years of storage [17]. Since all samples
were immediately frozen at 80 C following collection and
centrifugations, and processed at the same time and using the
same approach, any interference from ex vivo oxidations would
be limited and would apply equally to each clinical group of
samples. A third limitation of our study was that the limit of
detection and the recovery rate of M148(O) concentrations on
ApoA-I by MRM were not determined. We used an S/N ratio cut off
of >3 as the detection limit for all of the analyzed peptides.
However, the M148(O) oxidation peak area was well above this
ratio (as shown in Fig. 1). A fourth limitation is batch-to-batch
variation or auto digestion that can result from using different
lots of trypsin. We have used multiple transitions per peptide and
fresh trypsin match to minimize this source of variation. Finally,
our clinical findings are a proof-of-concept demonstration, and
need to be validated in larger clinical studies.
5. Conclusion
We conclude that MRM can be applied to monitor the relative
abundance of M148 ApoA-I oxidation. This approach would
facilitate examining the relationship between M148 oxidation
and vascular complications in CVD studies.
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